Back to search
FDAFDA · Food and drugs·Recall number Z-0641-2024

CD11b APC: ASR, REF: 340936, and CE, REF: 333143

Published January 17, 2024 · Recall initiated: October 25, 2023

Summary

FDA records medical device Class II recall Z-0641-2024, published January 17, 2024 and initiated October 25, 2023. Recalling firm: Becton, Dickinson and Company, BD Biosciences; Status: Ongoing; Reported quantity: 464 Vials; Lot: REF/UDI-DI/Expiration: 340936/00382903409365/20250228; 333143/00382903331437/20250228. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

In vitro diagnostics product that impacts the quality of cell staining can cause low or dim fluorescence signal, which can lead to potential false negative results and misdiagnosis of hematological malignancy, delayed treatment, and the need for additional patient samples.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton, Dickinson and Company, BD Biosciences
Distributor
Worldwide - US Nationwide distribution including in the states of IL, MN, FL, MI, MD, NC, NY, CA, GA, AR, KS, PA, NH, TX, OK, MA, MO, DC, AZ, IN, NJ, TN, WA, VA, CT and the countries of CA, BE, SG, HK, TW, BR, MY, IN, BO, PE, JP, MX, CL, KR, UY, AU.
Lot
REF/UDI-DI/Expiration: 340936/00382903409365/20250228; 333143/00382903331437/20250228
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was CD11b APC: ASR, REF: 340936, and CE, REF: 333143 recalled?

Yes. FDA published recall Z-0641-2024 on January 17, 2024. Reported hazard: In vitro diagnostics product that impacts the quality of cell staining can cause low or dim fluorescence signal, which can lead to potential false negative results and misdiagnosis of hematological malignancy, delayed treatment, and the need for additional patient samples.

What should I do if I have this product?

Voluntary: Firm initiated · Letter